User:Tinarss/Estrone/progesterone
We plan to separate the combination medication and address the following: side effects, adverse effects, contraindications, indications, availability, and pricing.
role in pediatrics
Amenorrhea
is the absence of one or more menstrual periods. [1]
Estrone:
Side Effects:
Adverse Effects:
Contraindications:
Indications:
Availability:
Pricing
Progesterone:
[5] Progesterone can also be used to prevent giving birth too soon. In women who are pregnant with a single fetus, asymptomatic in the prenatal stage, and at a high risk of giving pre-term birth spontaneously (going into labor spontaneously before 34 weeks), vaginal progesterone has been found to be effective in preventing spontaneous pre-term birth. Women who are at a high risk of giving pre-term birth spontaneously are those who have a short cervix of less than 25 mm or have previously given pre-term birth spontaneously. Although pre-term births are generally considered to be less than 37 weeks, vaginal progesterone is associated with fewer pre-term births of less than 34 weeks.
[6] Autoimmune progesterone dermatitis (APD) is a rare skin condition that develops as a reaction to too much progesterone in the body during the menstrual cycle.
[7] Current data shows that micronized progesterone, which is chemically identical to the progesterone produced in women's bodies, in combination with estrogen in menopausal hormone therapy does not seem to have significant effects on venous thromboembolism (blood clots in the veins), and ischemic stroke (lack of blood flow to the brain due to blockage of a blood vessel that supplies the brain). However, more studies need to be conducted to see whether or not micronized progesterone alone or in combined menopausal hormone therapy changes the risk of heart attacks.
[8] [9] Despite suggestions for using hormone therapy to prevent loss of muscle mass in post-menopausal women (women who are 50 years or older), menopausal hormone therapy involving either estrogen alone or estrogen and progesterone has not been found to preserve muscle mass. Menopausal hormone therapy also does not result in body weight reduction, BMI reduction, or change in glucose metabolism.
[10] Micronized progesterone cream and micronized progesterone in combined menopausal hormone therapy are both beneficial in preventing skin aging in post-menopausal women. However, there have not been any studies done yet on the effects of micronized progesterone on hair loss due to menopause.
[11] Transdermal progesterone (skin patch) and oral micronized progesterone have each been shown to be effective treatments for certain symptoms of menopause such as hot flashes and night sweats, otherwise known as vasomotor symptoms or VMS.
Side Effects:
Adverse Effects:
Contraindications:
Indications:
Availability:
Pricing:
 | This is the sandbox page where you will draft your initial Wikipedia contribution.
If you're starting a new article, you can develop it here until it's ready to go live. If you're working on improvements to an existing article, copy only one section at a time of the article to this sandbox to work on, and be sure to use an edit summary linking to the article you copied from. Do not copy over the entire article. You can find additional instructions here. Remember to save your work regularly using the "Publish page" button. (It just means 'save'; it will still be in the sandbox.) You can add bold formatting to your additions to differentiate them from existing content. |
Article Draft
Lead
Article body
References
- ^ King, Elizabeth M.; Albert, Arianne Y.; Murray, Melanie C.M. (2019-03-01). "HIV and amenorrhea: a meta-analysis". AIDS. 33 (3): 483–491. doi:10.1097/QAD.0000000000002084. ISSN 0269-9370.
- ^ academic.oup.com https://academic.oup.com/crawlprevention/governor?content=%2fjcem%2farticle%2f100%2f11%2f4021%2f2836077. Retrieved 2023-07-26.
{{cite web}}: Missing or empty|title=(help) - ^ Jarde, A; Lutsiv, O; Beyene, J; McDonald, Sd (2019-04). "Vaginal progesterone, oral progesterone, 17-OHPC, cerclage, and pessary for preventing preterm birth in at-risk singleton pregnancies: an updated systematic review and network meta-analysis". BJOG: An International Journal of Obstetrics & Gynaecology. 126 (5): 556–567. doi:10.1111/1471-0528.15566.
{{cite journal}}: Check date values in:|date=(help) - ^ Stewart, Lesley A; Simmonds, Mark; Duley, Lelia; Llewellyn, Alexis; Sharif, Sahar; Walker, Ruth AE; Beresford, Lucy; Wright, Kath; Aboulghar, Mona M; Alfirevic, Zarko; Azargoon, Azam; Bagga, Rashmi; Bahrami, Elham; Blackwell, Sean C; Caritis, Steve N (2021-03). "Evaluating Progestogens for Preventing Preterm birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials". The Lancet. 397 (10280): 1183–1194. doi:10.1016/s0140-6736(21)00217-8. ISSN 0140-6736.
{{cite journal}}: Check date values in:|date=(help) - ^ Care, Angharad; Nevitt, Sarah J; Medley, Nancy; Donegan, Sarah; Good, Laura; Hampson, Lynn; Tudur Smith, Catrin; Alfirevic, Zarko (2022-02-15). "Interventions to prevent spontaneous preterm birth in women with singleton pregnancy who are at high risk: systematic review and network meta-analysis". BMJ: e064547. doi:10.1136/bmj-2021-064547. ISSN 1756-1833. PMC 8845039. PMID 35168930.
{{cite journal}}: CS1 maint: PMC format (link) - ^ Lipman, Zoe M.; Labib, Angelina; Vander Does, Ashley; Yosipovitch, Gil (2022). "Autoimmune Progesterone Dermatitis: A Systematic Review". Dermatitis. 33 (4): 249–256. doi:10.1097/DER.0000000000000779. ISSN 2162-5220.
- ^ Kaemmle, L. M.; Stadler, A.; Janka, H.; von Wolff, M.; Stute, P. (2022). "The impact of micronized progesterone on cardiovascular events – a systematic review". Climacteric. 25 (4): 327–336. doi:10.1080/13697137.2021.2022644. ISSN 1369-7137.
- ^ Javed, Ayesha A.; Mayhew, Alexandra J.; Shea, Alison K.; Raina, Parminder (2019). "Association Between Hormone Therapy and Muscle Mass in Postmenopausal Women: A Systematic Review and Meta-analysis". JAMA Network Open. 2 (8): e1910154. doi:10.1001/jamanetworkopen.2019.10154. ISSN 2574-3805. PMC 6716293. PMID 31461147.
{{cite journal}}: CS1 maint: PMC format (link) - ^ Coquoz, A.; Gruetter, C.; Stute, P. (2019). "Impact of micronized progesterone on body weight, body mass index, and glucose metabolism: a systematic review". Climacteric. 22 (2): 148–161. doi:10.1080/13697137.2018.1514003. ISSN 1369-7137.
- ^ Gasser, S.; Heidemeyer, K.; von Wolff, M.; Stute, P. (2021). "Impact of progesterone on skin and hair in menopause – a comprehensive review". Climacteric. 24 (3): 229–235. doi:10.1080/13697137.2020.1838476. ISSN 1369-7137.
- ^ Dolitsky, Shelley N.; Cordeiro Mitchell, Christina N.; Stadler, Sarah Sheehan; Segars, James H. (2021). "Efficacy of progestin-only treatment for the management of menopausal symptoms: a systematic review". Menopause. 28 (2): 217–224. doi:10.1097/GME.0000000000001676. ISSN 1530-0374.